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Docetaxel is cost-effective and should be used as adjuvant treatment and considered 
as therapeutic option for MBC.
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OBJECTIVES: Bevacizumab, known as VEGF inhibitor, has demonstrated signiﬁcant 
activity when it is used with cytotoxic chemotherapy together in metastatic colorectal 
cancer(mCRC). However, bevacizumab is an expensive medication known as not 
cost-effectiveness with high ICER(Incremental Cost-Effectiveness Ratio) in other coun-
tries. The purpose of this study was to examine the economic efﬁciency of treating 
mCRC with bevacizumab plus chemotherapy versus chemotherapy alone from the 
perspective of the social aspects in Korea. METHODS: Markov model was developed 
to compare the cost and beneﬁts of adding bevacizumab to oxaliplatin plus FU/
LV(FOLFOX) or capecitabine plus FU/LV(CapeOX) with FOLFOX or CapeOX 
alone. We searched clinical documentation, extracted median time to progression and 
median overall survival from each chemotherapy, and calculated the transition prob-
ability and death rate per cycle. Model simulates costs and outcomes in hypothetical 
cohort of metastatic colorectal cancer for 5 years with 5% discount rate. We included 
that direct and non-direct medical cost(2009). The ICERs were calculated from incre-
mental life-years gained(LYG) and incremental costs between single and combination 
therapy. Sensitivity analyses were performed on crucial parameters. RESULTS: 
After markov model simulation for 5 years, FOLFOXbevacizumab gained 1.58 
years/patient and FOLFOX 1.42 years/patient, whereas CapeOXbevacizumab 1.57 
years/patient and CapeOX 1.31 years/patient. Total cost of FOLFOXbevacizumab, 
FOLFOX, CapeOXbevacizumab, CapeOX are W88,567,199($70,854), 
W73,938,752($59,151), W91,904,773($73,524), W43,864,530($35,092), respec-
tively. The ICERs of additional bevacizumab when combined with FOLFOX, CapeOX 
were W89,974,151 ($71,979), W181,331,641 ($145,065), respectively, per life year 
gained, proving very high in both case combination therapy. Sensitivity analysis 
showed that the price of bevacizumab is a key parameter of its cost-effectiveness. 
CONCLUSIONS: As a result, it is proven that the addition of bevacizumab to 
FOLFOX, CapeOX in mCRC patients is expensive given clinical beneﬁt in terms of 
LYG in Korea. This ﬁndings may offer one of the useful basic data selecting chemo-
therapy regimens in treating for mCRC.
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OBJECTIVES: Colorectal cancer (CRC) is the third most common cancer in the 
UK. In 2007 the UK NHS introduced a CRC screening programme using the faecal 
occult blood test (FOBT) for biennial screening of individuals aged 60 to 69. CT 
colonography (CTC) is an alternative technology for CRC screening with the potential 
to prevent cancer by detecting pre-cancerous polyps as well as detecting cancer at an 
early stage. This economic analysis assessed the cost-effectiveness of CTC for CRC 
screening from the UK NHS perspective. METHODS: A state-transition Markov 
model was constructed to simulate the lifetime experience of a cohort of individuals 
screened under a range of scenarios using four different CRC screening technologies: 
FOBT, ﬂexible sigmoidoscopy, optical colonoscopy and CTC. The model estimated 
lifetime costs and health outcomes; the cost-effectiveness measure was incremental 
cost per Quality Adjusted Life Year (QALY). The impact of uncertainty in underlying 
model parameters was evaluated in one-way and probabilistic sensitivity analyses. 
RESULTS: CTC screening every 10 years for individuals aged 60–69 was less expen-
sive and yielded greater health beneﬁts (QALYs and life years) compared to no screen-
ing or the current UK programme of biennial FOBT screening. Compared to biennial 
FOBT, 10-yearly CTC screening for 60–69 year olds is estimated to avoid 661 more 
cases of CRC and 364 more deaths per 100,000 people invited for screening. CTC 
was cost-effective under a range of assumptions. The model ﬁt to observed epidemiol-
ogy data well, and was robust to changes in underlying parameter values. CONCLU-
SIONS: CTC has the potential to provide a cost-effective option for CRC screening 
and may be cost saving compared to the current programme of biennial FOBT.
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OBJECTIVES: Although several clinical and biological parameters are prognostic 
factors, their medico-economic impact in the prescription of erlotinib has never been 
evaluated. A French NCI prospective study aimed to determine the cost of manage-
ment of advanced NSCLC patients (pts) treated by erlotinib and to evaluate the cost-
effectiveness ratio in populations selected on clinical-guided or biomarkers-guided 
arguments. METHODS: Prospective cohort of consecutive advanced NSCLC pts 
newly treated by erlotinib and followed until progression or death. Direct medical 
costs, including erlotinib and hospitalization costs were computed from the health 
care system perspective with a time horizon of 2 years. Cost-effectiveness ratios (CER) 
were calculated as management cost divided by the number of days of life remaining 
(DOLR) when the treatment is initiated, in all patients, in clinical-selected patients 
(non/ex-smoking women with non-squamous cell carcinoma (SCC) histology) and in 
biomarker-selected patients. RESULTS: A total of 522 patients were enrolled between     
02/07 and 03/08. Median age was 62 years; 32% were females; 63% had adenocar-
cinoma. With a 15.5 months (mo.) median follow-up, median PFS and OS were 
respectively 2.4 and 5.6 mo. Mean management cost was 10284       o a8562 per patient, 
with a median of 170 days remaining to live at initiation of erlotinib treatment (a60 /
DOLR). Direct erlotinib cost represented 78% of the cost. Non-smoking women with 
non-SCC histology lived 133 days longer than other patients (279 and 146 days 
respectively), resulting in an extra-cost management of a2637 due to a longer erlotinib 
treatment. CER was however lower (a44/DOLR) in non-smoking women with non 
SCC histology than in other patients (a66/DOLR). CER of biomarkers-selected 
patients will be available for the congress. CONCLUSIONS: Clinical-guided argu-
ments allowed to identify patients with lower management costs per day of life 
remaining to live. Planned analyses would evaluate the impact of biomarkers in term 
of cost of management per day of life remaining.
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OBJECTIVES: Adjuvant chemotherapy is used to reduce the risk of relapse after 
surgery. Its limited efﬁcacy in breast cancer must be weighed against induced toxicities 
and cost. The selection of patients eligible for adjuvant chemotherapy is based 
on prognostic factors. Genomic signatures would improve patient selection for adju-       
vant chemotherapy and avoid overtreatment. The aim of this study is to compare the            
cost -effectiveness of different prognosis -based selection strategies in the French 
context. METHODS: We used a model -based simulation. Population characteristics, 
survival and hospital costs (chemotherapy, chemotherapy -induced toxicities and 
relapses) were estimated using a patient -level data set from a retrospective cohort 
of patients followed -up at Gustave Roussy Institute since 1990. All patients 
were node -negative and metastasis -free after initial surgery. The other model param-
eters (chemotherapy efﬁcacy, sensitivity and speciﬁcity of prognosis -based selection 
strategies) were obtained from literature. The cost analysis was conducted from a 
third -party payer’s perspective. We used a strategy with no adjuvant chemotherapy 
as a reference for cost -effectiveness comparisons. RESULTS: The retrospective 
cohort study consisted of 910 women with breast cancer. The mean age was 57 
(range: 23–93). Thirty-one percent of patients were Scarff -Bloom grade I, 43% 
grade II and 19% grade III (7% grade missing). The mean tumor size was 19 mm 
(range: 1–120). Thirty-two percent of the women received adjuvant chemotherapy 
alone or combined with another adjuvant treatment. The median follow-up after 
surgery was 87 months. The median survival time was 209 months. The distant relapse 
rate was 10.7%. The cost of adjuvant chemotherapy was a3,083 (standard deviation: 
a307) and the cost of distant relapse a33,692 (range: a847–a112,710). Cost -effective-
ness analysis is in progress. Results will be available for the meeting. CONCLUSIONS: 
This is the ﬁrst French study to assess the cost -effectiveness of using prognostic 
information to select women eligible for adjuvant chemotherapy in early breast 
cancer.
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OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) of imiquimod compared 
to no treatment in patients with superﬁcial basal cell carcinoma and contraindication 
to surgical intervention and cryotherapy in Poland. METHODS: This analysis was 
based on a decision model regarding clinical effects of imiquimod in comparison to 
placebo (vehicle cream), obtained from randomized clinical trials. The population was 
deﬁned as adult patients with superﬁcial basal cell carcinoma (sBCC) and contraindi-
cation to surgical intervention/cryotherapy, also patients, who do not give consent to 
these forms of treatment. Clinical and histological complete clearance were assessed 
as health outcomes. Direct medical costs of the analysed therapies were estimated from 
the perspective of both payers in Poland (National Health Fund and patient). We 
included costs of medication, clinic visits and diagnostic assessments. Time horizon 
of the analysis was 18 weeks. Treatment was assumed as once a day 5x/week for 6 
weeks. Costs and effects were not discounted. RESULTS: Probability of complete 
clearance, assessed clinically and histologically was 0.751 for patients treated with 
imiquimod and 0.017 when placebo was used. Probability of histological complete 
clearence was 0.822 and 0.031, respectively. Total costs of imiquimod therapy were 
estimated at 1,075.30 PLN, while costs of no treatment were 174.80 PLN. Incremental 
